Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Delaware
Clinical trial register · United States · industry-sponsored

Clinical Trials in Delaware, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca21 BioMarin Pharmaceutical7 Janssen Research & Development, LLC6 Amgen6 AbbVie5
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in Delaware

179 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Recruiting
Trevi Therapeutics
Phase 3
201
Delaware, Florida, North Carolina, Texas
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois
2026-09-29
Not yet open
Reduction of Anxiety Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07140497Hearing Disability, Anxiety, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Not yet open
Reduction of Depression Through Dual Treatment: Digital CBT & NBHWC Coaching
NCT07195292Hearing Disability, Depression, Mobility Disability
Toivoa Inc
Not applicable
200
Delaware, New Jersey, Ohio, Texas
2026-09
Recruiting
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
AstraZeneca
Observational
8,000
Delaware
2026-08-03
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Recruiting
Thinks Works, PBC
Not applicable
30
Delaware
2026-05-28
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
390
California, Colorado, Delaware, Illinois, Indiana, Missouri, Ohio, Oregon
2026-05-11
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
Theranica
Not applicable
100
Delaware, Mississippi, New York, Virginia
2026-05-04
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
California, Delaware, Illinois, Maryland, Ohio, Pennsylvania, Texas
2026-04-20
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Active, closed
Human Optimization Project
Not applicable
35
Delaware
2026-03-01
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
By invitation
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388Non Small Cell Lung Cancer
N-Power Medicine
Observational
650
California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas
2026-01-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Alaska, Arizona, Arkansas, California, Delaware, Florida, Idaho, Illinois
2026-01-02
Recruiting
Ascendis Pharma A/S
Phase 3
186
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho, Louisiana
2025-12-12
Recruiting
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2025-11-18
Recruiting
Granata Bio Corporation
Phase 3
659
California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Maryland
2025-11-01
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
Tezspire Cardiac Events PASS
NCT06951867Cardiovascular Events, MACE
DrugTezepelumab
AstraZeneca
Observational
16,640
Delaware
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Louisiana
2025-09-11
Recruiting
BeOne Medicines
Phase 3
500
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa
2025-09-04
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
153
Delaware, District of Columbia, Florida, Georgia, Massachusetts, Missouri, Ohio, West Virginia
2025-08-21
Recruiting
Autologous Adipose Cells Therapy
NCT06869252Hair Loss/Baldness, Wrinkle Appearance, Volume, Fine Lines
CERM INC.
Phase 1/2
40
Delaware
2025-08-01
Recruiting
Amgen
Phase 3
12,800
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2025-07-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Colorado, Delaware, Florida, Kentucky, New Jersey
2025-07-21
Recruiting
AstraZeneca
Phase 2
100
Delaware, District of Columbia, Kansas, Michigan, New York, Pennsylvania
2025-07-17
Recruiting
CorMedix Therapeutics
Phase 4
36
Alabama, Arizona, California, Delaware, New Jersey, Texas
2025-07-08
By invitation
BioMarin Pharmaceutical
Phase 3
140
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Minnesota, Missouri
2025-06-20
Recruiting
GlaxoSmithKline
Phase 3
981
California, Delaware, Florida, Georgia, Illinois, Maryland, Michigan, Missouri
2025-06-20
Recruiting
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Alabama, Arizona, Arkansas, California, Colorado, Delaware, Florida, Illinois
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2025-06-04
Recruiting
Eikon Therapeutics
Phase 2/3
740
Arizona, Arkansas, California, Colorado, Delaware, Florida, Maryland, Missouri
2025-05-22
Recruiting
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois
2025-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-04-11
Recruiting
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Not yet open
Below-the-Knee Interventions for Limb Salvage: Use of Multifunctional Angioplasty Balloon Catheters
NCT06906055Peripheral Arterial Disease Below the Knee, Peripheral Arterial Disease, Rutherford 4 and 5 with Possibility to Improve Vascularization
Summa Therapeutics, LLC
Not applicable
24
Delaware, New Jersey
2025-04-03
Recruiting
AstraZeneca
Phase 2
540
California, Delaware, Florida, Idaho, Indiana, Iowa, Kansas, Kentucky
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Active, closed
Averitas Pharma, Inc.
Observational
144
Delaware, Georgia, Kentucky, New Jersey, Ohio, Pennsylvania
2025-03-14
Recruiting
Tyra Biosciences, Inc
Phase 2
92
California, Colorado, Delaware, Maryland, Missouri, North Carolina, Tennessee, Texas
2025-03-04
Recruiting
AstraZeneca
Phase 3
840
Alaska, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-03-01
Recruiting
Novo Nordisk A/S
Phase 3
510
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-02-17
Recruiting
Sequenom, Inc.
Observational
6,550
Arizona, Delaware, Florida, Louisiana, Massachusetts, New Jersey, New York, North Carolina
2025-02-02
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2/3
650
Alabama, Arizona, California, Colorado, Delaware, Florida, Illinois, Iowa
2025-01-28
Active, closed
AbbVie
Phase 2
150
Arkansas, California, Connecticut, Delaware, Florida, New York, Ohio, Tennessee
2025-01-20
Recruiting
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
NCT06824064Metastatic Colorectal Cancer, Advanced Colorectal Cancer
DrugRBS2418
Riboscience, LLC.
Phase 2
150
Delaware, Texas
2025-01-17
Recruiting
Takeda
Phase 4
78
Alabama, Arizona, California, Delaware, Florida, Georgia, Illinois, Indiana
2025-01-14
Recruiting
Immunovant Sciences GmbH
Phase 2
240
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2024-12-17
Recruiting
Janssen Research & Development, LLC
Phase 2
480
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-12-16
Active, closed
ViiV Healthcare
Phase 3
326
Alabama, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2024-12-02
Recruiting
AstraZeneca
Phase 3
1,160
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-11-27
Recruiting
CoMind Early Feasibility Study
NCT06368648Intracranial Pressure, Intracranial Pressure Changes, Traumatic Brain Injury, Intracerebral Hemorrhage
CoMind Technologies Limited
Observational
581
Arizona, California, Delaware, District of Columbia, Florida, Iowa, Kansas, Missouri
2024-11-27
Active, closed
BioMarin Pharmaceutical
Phase 2
30
California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana
2024-11-22
Recruiting
Ensoma
Observational
60
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
NCT06492733Chronic Total Occlusion of Artery of the Extremities
Versono Medical Ltd
Not applicable
65
Delaware, Florida, Iowa, Louisiana, Michigan, Tennessee
2024-11-05
Recruiting
Nerviano Medical Sciences
Phase 1
124
California, Colorado, Delaware, Georgia, Minnesota, Ohio, Texas
2024-10-16
Active, closed
Merus B.V.
Phase 3
699
Alabama, California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kentucky
2024-09-25
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho
2024-08-30
Recruiting
AstraZeneca
Phase 3
1,018
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2024-08-07
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
Allogene Therapeutics
Phase 2
250
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2024-06-18
Active, closed
BioMarin Pharmaceutical
Phase 3
80
Delaware, District of Columbia, Illinois, Wisconsin
2024-06-17
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Iowa
2024-06-03
Recruiting
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
134
California, Colorado, Delaware, Georgia, Illinois, Indiana, Maryland, Minnesota
2024-05-28
Recruiting
AstraZeneca
Phase 3
440
Alaska, Arizona, Arkansas, California, Colorado, Delaware, Florida, Georgia
2024-05-20
Active, closed
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC)
DrugsKeytruda·Pembrolizumab
Inhibrx Biosciences, Inc
Phase 2/3
410
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, Michigan, Missouri
2024-05-14
Active, closed
Complement Theory Inc.
Not applicable
146
Delaware
2024-05-12
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2024-05-06
Recruiting
CSL Behring
Phase 2/3
3,110
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-04-27
Active, closed
Amgen
Phase 3
111
Alabama, Arizona, California, Delaware, Florida, Georgia, Indiana, Maryland
2024-04-22
By invitation
Pivotal Trial of the Boomerang Catheter for pDVA
NCT06311773Chronic Limb-Threatening Ischemia
Aveera Medical, Inc.
Not applicable
120
California, Delaware, Florida, Illinois, Louisiana, Massachusetts, New Hampshire, New Jersey
2024-04-16
Active, closed
GlaxoSmithKline
Phase 4
1,358
Alabama, Arkansas, California, Delaware, Florida, Illinois, Louisiana, Maine
2024-04-16
Recruiting
Translational Sciences, Inc.
Phase 2
300
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2024-03-18
Active, closed
Genmab
Phase 3
1,095
California, Colorado, Delaware, Florida, Idaho, Illinois, Indiana, Iowa
2024-02-05
Active, closed
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Active, closed
Idorsia Pharmaceuticals Ltd.
Observational
2,095
Delaware
2023-11-30
Recruiting
BioMarin Pharmaceutical
Observational
400
Arizona, California, Delaware, District of Columbia, Illinois, Maryland, Massachusetts, Minnesota
2023-11-27
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Recruiting
Takeda
Phase 3
80
Delaware, Florida, Illinois, Nebraska, Ohio, Texas
2023-11-13
Active, closed
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Recruiting
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211Single Ventricle Heart Disease
Mezzion Pharma Co. Ltd
Phase 3
436
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-10-25
Active, closed
AstraZeneca
Phase 3
5,511
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2023-10-05
Recruiting
DalCor Pharmaceuticals
Phase 3
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-10-03
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2023-09-14
By invitation
Ascendis Pharma Growth Disorders A/S
Phase 2/3
140
Arkansas, Colorado, Delaware, Minnesota, Montana, New York, Texas, Wisconsin
2023-06-21
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
69
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2023-06-14
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-04-11
Recruiting
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
Schrödinger, Inc.
Phase 1
98
Arizona, Delaware, Florida, Massachusetts, New Jersey, New York, North Carolina, Ohio
2023-04-10
Recruiting
AbbVie
Phase 1
210
Arizona, Arkansas, Colorado, Delaware, Illinois, Indiana, Louisiana, Maryland
2023-03-21
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2023-01-25
Active, closed
Agenus Inc.
Phase 2
234
Arizona, California, Colorado, Delaware, Florida, Massachusetts, Michigan, New Jersey
2022-11-30
Recruiting
Sanofi
Phase 1/2
542
Delaware, Iowa, Kansas, Michigan, New Jersey, New York, Rhode Island, Texas
2022-11-29
Active, closed
AstraZeneca
Phase 3
1,174
Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2022-11-28
Active, closed
RESPONDER-HF Trial
NCT05425459Heart Failure, Heart Failure, Diastolic
Corvia Medical
Not applicable
750
Arizona, California, Delaware, Florida, Georgia, Illinois, Louisiana, Massachusetts
2022-11-17
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa
2022-10-25
Active, closed
Amgen
Phase 1
184
California, Delaware, Michigan, New Jersey, New York, North Carolina, South Dakota, Washington
2022-08-24
Active, closed
Novo Nordisk A/S
Phase 3
412
Alabama, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2022-08-10
Recruiting
N-Power Medicine
Observational
20,000
California, Delaware, Illinois, New Mexico, Pennsylvania, Texas
2022-08-01
Recruiting
NeuraLight
Observational
2,000
Delaware
2022-07-22
Active, closed
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
Xencor, Inc.
Phase 2
170
Arizona, California, Colorado, Delaware, Florida, Georgia, Michigan, Nevada
2022-07-21
Recruiting
Aspira Women's Health
Observational
1,200
Arizona, California, Delaware, Georgia, Indiana, Maryland, New York, Ohio
2022-07-12
Recruiting
Riboscience, LLC.
Phase 1
164
Arizona, California, Delaware, Kentucky, Louisiana, Maryland, New York, North Carolina
2022-07-11
Active, closed
Genmab
Phase 2
264
Arizona, Connecticut, Delaware, Florida, Georgia, Maryland, Missouri, New York
2022-06-14
Active, closed
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
Setrusumab vs Placebo for Osteogenesis Imperfecta
NCT05125809Osteogenesis Imperfecta
DrugSetrusumab
Ultragenyx Pharmaceutical Inc
Phase 2/3
183
Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2022-02-21
Active, closed
Genentech, Inc.
Phase 2
320
Alabama, Alaska, Arizona, California, Colorado, Delaware, Florida, Iowa
2022-02-01
Active, closed
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Prokidney
Phase 3
685
Alabama, Arizona, California, Delaware, Florida, Georgia, Idaho, Illinois
2022-01-05
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Illinois
2021-12-16
Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
DrugsZanzalintinib·Relatlimab·Yervoy·Ipilimumab
Exelixis
Phase 1
1,394
Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana
2021-12-14
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
300
California, Colorado, Delaware, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2021-12-06
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 2
222
Alabama, Arkansas, Delaware, Florida, Georgia, Iowa, Massachusetts, Michigan
2021-12-01
Active, closed
Tenaya Therapeutics
Observational
200
Arkansas, California, Colorado, Delaware, Florida, Missouri, New York, Ohio
2021-11-01
Active, closed
Emerald Clinical Inc.
Phase 2
39
California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Maryland
2021-10-21
Active, closed
Penumbra Inc.
Not applicable
229
California, Delaware, District of Columbia, Florida, Illinois, Indiana, Kentucky, Louisiana
2021-09-30
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Arizona, California, Colorado, Delaware, Idaho, Illinois, Maryland, Massachusetts
2021-09-20
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Alabama, Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2021-08-14
Recruiting
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
DrugSparsentan
Travere Therapeutics, Inc.
Phase 2
67
California, Delaware, Florida, Iowa, Massachusetts, Michigan, Minnesota, Missouri
2021-08-12
Active, closed
Boston Scientific Corporation
Phase 4
544
Alabama, California, Delaware, Georgia, Indiana, Kentucky, Maryland, Massachusetts
2021-08-02
Recruiting
Penumbra Inc.
Observational
1,500
California, Delaware, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana
2021-06-25
Active, closed
AstraZeneca
Phase 3
893
Arizona, California, Colorado, Connecticut, Delaware, Kentucky, Maryland, Massachusetts
2021-05-10
Recruiting
Gilead Sciences
Phase 1
30
California, Delaware, Maryland, Texas
2021-04-06
Recruiting
Boston Scientific Corporation
Observational
5,000
Arkansas, California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois
2021-03-29
Active, closed
Loxo Oncology, Inc.
Phase 3
238
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2021-03-09
Recruiting
Pfizer
Phase 3
2,100
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2021-01-15
Active, closed
SetPoint Medical Corporation
Phase 3
243
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2021-01-11
Active, closed
Sera Prognostics, Inc.
Not applicable
6,500
California, Connecticut, Delaware, Florida, Kentucky, Louisiana, Massachusetts, Michigan
2020-11-06
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, New York
2020-10-29
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2020-10-15
Recruiting
Epygenix
Phase 3
150
Alabama, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Illinois
2020-09-15
Active, closed
AbbVie
Phase 3
531
California, Colorado, Connecticut, Delaware, Florida, Idaho, Illinois, Indiana
2020-09-10
Active, closed
AbbVie
Phase 3
800
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2020-08-10
Active, closed
Tizona Therapeutics, Inc
Phase 1
240
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois
2020-07-14
Recruiting
Kaneka Medical America LLC
Not applicable
35
California, Delaware, Michigan, New York, North Carolina, Ohio, South Carolina, Virginia
2020-01-01
Active, closed
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Abiomed Inc.
Not applicable
527
Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida
2019-12-12
Active, closed
Chiesi USA, Inc.
Observational
5,050
California, Delaware, Florida, Idaho, Maryland, Massachusetts, Michigan, Missouri
2019-10-16
Active, closed
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 2
114
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2019-09-29
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
DrugsGEN1042·Adrucil·Nab-paclitaxel·Pemetrexed
Genmab
Phase 1/2
350
Alaska, California, Connecticut, Delaware, Florida, Illinois, Kentucky, Maryland
2019-09-17
Recruiting
RCDP Natural History Study
NCT04031287Rhizomelic Chondrodysplasia Punctata
MED-LIFE DISCOVERIES LP
Observational
75
Delaware
2019-06-18
Active, closed
BioMarin Pharmaceutical
Phase 2
73
California, Delaware, Georgia, Illinois, Ohio, Tennessee, Texas, Wisconsin
2019-06-12
Recruiting
Prolaio
Observational
2,000
Arizona, California, Delaware, Florida, Illinois, Minnesota, Texas, Utah
2019-06-06
Active, closed
AstraZeneca
Phase 3
724
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Georgia, Illinois
2019-03-06
Active, closed
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
DrugsAdagrasib·Afatinib·Cetuximab·Pembrolizumab
Mirati Therapeutics Inc.
Phase 1/2
731
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2019-01-15
Active, closed
9-ING-41 in Patients With Advanced Cancers
NCT03678883Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer
DrugsCCNU·Lomustine·Abraxane·Adriamycin
Actuate Therapeutics Inc.
Phase 2
350
Arizona, California, Delaware, District of Columbia, Florida, Illinois, Iowa, Kansas
2019-01-04
Recruiting
BioDelivery Sciences International
Observational
34,532
Delaware
2019-01-04
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Active, closed
Janssen Research & Development, LLC
Phase 3
84
California, Colorado, Connecticut, Delaware, Georgia, Minnesota, New York, Tennessee
2018-10-29
Active, closed
Daiichi Sankyo
Phase 1/2
65
California, Colorado, Delaware, District of Columbia, Georgia, Minnesota, Ohio, Pennsylvania
2018-08-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
797
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana
2018-04-24
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
Massive Bio, Inc.
Observational
50,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2018-01-01
Active, closed
BioMarin Pharmaceutical
Phase 3
119
California, Delaware, Georgia, Illinois, Maryland, Missouri, Ohio, Texas
2017-12-12
Recruiting
Agendia
Observational
30,000
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida
2017-04-28
Recruiting
Stryker Instruments
Observational
8,000
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2017-03-10
Recruiting
Kaneka Medical America LLC
Not applicable
35
California, Delaware, Florida, Michigan, Minnesota, New York, North Carolina, Ohio
2015-05-03
Active, closed
Eli Lilly and Company
Phase 3
453
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Indiana
2014-10-03
Active, closed
AstraZeneca
Phase 3
1,837
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2014-04-22
Active, closed
MedImmune LLC
Phase 2
571
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Maryland
2013-05-17
Active, closed
Genentech, Inc.
Phase 2
378
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2008-10-16
Active, closed
Janssen Scientific Affairs, LLC
Observational
20,167
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2007-06-21
Rows per page Showing 1–179 of 179
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/delaware

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 179 of those studies with a site in Delaware.

How many clinical trials are recruiting in Delaware?

102 of the 179 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 68 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Delaware), 179 studies
PhaseStudiesRecruitingShare
Phase 3804544.7%
Phase 2281315.6%
Observational262114.5%
Not applicable1759.5%
Phase 2/31075.6%
Phase 1864.5%
Phase 1/2633.4%
Phase 4422.2%

Most active sponsors

Lead sponsors with the most studies (Delaware)
Lead sponsorStudiesRecruiting
AstraZeneca2115
BioMarin Pharmaceutical72
Amgen63
Janssen Research & Development, LLC63
AbbVie51
Bristol-Myers Squibb53
Merck Sharp & Dohme LLC54
Boston Scientific Corporation31
Genmab30
Mirati Therapeutics Inc.32
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.